Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush ...
Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...
On 31 March, at the American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago, US, the findings from the PURSUIT Phase IIb clinical trial were presented. The study evaluated the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
An investigational drug, currently known as AZD0780, lowers low-density-lipoprotein cholesterol (LDL-C) to target levels in most patients whose cholesterol is still over target despite statin therapy, ...
The study, officially titled “A Fixed-sequence, Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Metformin in Healthy Volunteers,” aimed to see how AstraZeneca’s ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A once-daily oral PCSK9 inhibitor reduced LDL in ...
AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results